Articles
High-grade serous ovarian cancers with deficient homologous DNA repair are particularly sensitive to maintenance therapies including the PARP inhibitor olaparib. This repair deficit generates genomic tumoral “scars.” It is therefore essential to identify patients whose tumors have this repair defici...